BIORA THERAPEUTICS, INC. short interest in 2023
In 2023, BIORA THERAPEUTICS, INC.'s disclosed short interest ran from 3.57% of shares outstanding on 31 Mar 2023 to 1.89% on 29 Dec 2023, a change of -1.68 percentage points. The year's high was 3.66% on 31 Oct 2023 and its low 1.24% on 30 Nov 2023, averaging 2.76% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.22 days on 14 Apr 2023. Full history: BIORA THERAPEUTICS, INC..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024
2023 in figures
- Start of year
- 3.57% (31 Mar 2023)
- End of year
- 1.89% (29 Dec 2023)
- Change
- -1.68 pp
- High
- 3.66% (31 Oct 2023)
- Low
- 1.24% (30 Nov 2023)
- Average
- 2.76%
- Highest days to cover
- 7.22 (14 Apr 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Mar 2023 | 3.57% | 3.10 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 3.57% | 7.22 | |
| 28 Apr 2023 | 3.58% | 6.98 | |
| 15 May 2023 | 3.30% | 2.90 | 10-Q filed, results (8-K) |
| 31 May 2023 | 3.48% | 1.15 | |
| 15 Jun 2023 | 3.47% | 1.19 | |
| 30 Jun 2023 | 3.13% | 3.20 | |
| 14 Jul 2023 | 2.31% | 3.64 | |
| 31 Jul 2023 | 2.01% | 3.32 | |
| 15 Aug 2023 | 1.46% | 3.61 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 1.33% | 3.37 | |
| 15 Sep 2023 | 2.25% | 2.70 | |
| 29 Sep 2023 | 3.12% | 2.69 | |
| 13 Oct 2023 | 3.41% | 5.54 | |
| 31 Oct 2023 | 3.66% | 2.43 | |
| 15 Nov 2023 | 2.76% | 2.92 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 1.24% | 1.00 | |
| 15 Dec 2023 | 2.85% | 1.00 | |
| 29 Dec 2023 | 1.89% | 1.00 |
See also: BIORA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.